Moderna stock price forecast

Last week's US$4.4b market cap gain would probably be appreciated by institutional investors, especially after a year of 38% losses. The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance. The Moderna stock price forecast shows sector-relative strength versus biotech peers. Beta at 1.35 indicates higher volatility, meaning both downside risk toward $94 and explosive upside toward $115 remain statistically probable.